Nothing Special   »   [go: up one dir, main page]

SG11202005049QA - Exosomes for immuno-oncology and anti-inflammatory therapy - Google Patents

Exosomes for immuno-oncology and anti-inflammatory therapy

Info

Publication number
SG11202005049QA
SG11202005049QA SG11202005049QA SG11202005049QA SG11202005049QA SG 11202005049Q A SG11202005049Q A SG 11202005049QA SG 11202005049Q A SG11202005049Q A SG 11202005049QA SG 11202005049Q A SG11202005049Q A SG 11202005049QA SG 11202005049Q A SG11202005049Q A SG 11202005049QA
Authority
SG
Singapore
Prior art keywords
exosomes
oncology
immuno
inflammatory therapy
inflammatory
Prior art date
Application number
SG11202005049QA
Inventor
Nuruddeen Lewis
Yu Zhou
Sriram Sathyanarayanan
John Kulman
Douglas Williams
Leonid Gaydukov
Ke Xu
Shelly Martin
Original Assignee
Codiak Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codiak Biosciences Inc filed Critical Codiak Biosciences Inc
Publication of SG11202005049QA publication Critical patent/SG11202005049QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Botany (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202005049QA 2017-12-28 2018-12-28 Exosomes for immuno-oncology and anti-inflammatory therapy SG11202005049QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762611140P 2017-12-28 2017-12-28
US201862723267P 2018-08-27 2018-08-27
PCT/US2018/068062 WO2019133934A2 (en) 2017-12-28 2018-12-28 Exosomes for immuno-oncology and anti-inflammatory therapy

Publications (1)

Publication Number Publication Date
SG11202005049QA true SG11202005049QA (en) 2020-07-29

Family

ID=67058801

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005049QA SG11202005049QA (en) 2017-12-28 2018-12-28 Exosomes for immuno-oncology and anti-inflammatory therapy

Country Status (16)

Country Link
US (3) US10723782B2 (en)
EP (1) EP3731849A4 (en)
JP (2) JP7507090B2 (en)
KR (1) KR20200108275A (en)
CN (1) CN111655271A (en)
AU (1) AU2018394238A1 (en)
BR (1) BR112020013131A2 (en)
CA (1) CA3085471A1 (en)
CL (1) CL2020001691A1 (en)
CO (1) CO2020009091A2 (en)
EA (1) EA202091134A1 (en)
IL (1) IL275600A (en)
MX (1) MX2020006672A (en)
PH (1) PH12020550805A1 (en)
SG (1) SG11202005049QA (en)
WO (1) WO2019133934A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2578394A (en) 2017-08-07 2020-05-06 Univ California Platform for generating safe cell therapeutics
SG11202005049QA (en) 2017-12-28 2020-07-29 Codiak Biosciences Inc Exosomes for immuno-oncology and anti-inflammatory therapy
AU2019234654B2 (en) * 2018-03-12 2024-09-26 Board Of Regents, The University Of Texas System Immuno-exosomes and methods of use thereof
WO2019199941A1 (en) 2018-04-10 2019-10-17 Northwestern University Extracellular vesicles comprising targeting affinity domain-based membrane proteins
AU2020289326A1 (en) * 2019-06-04 2022-01-27 Thomas Jefferson University Oligodendrocyte-derived extracellular vesicles for therapy of multiple sclerosis
WO2021003425A1 (en) * 2019-07-03 2021-01-07 Codiak Biosciences, Inc. Methods of inducing hematopoiesis
CA3152488A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Combination therapy using extracellular vesicles
WO2021062317A1 (en) * 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Extracellular vesicle compositions
US20240319195A1 (en) * 2019-10-15 2024-09-26 Cornell University Methods for detecting and inhibiting brain metastasis
EP4090974A1 (en) 2020-01-17 2022-11-23 Codiak BioSciences, Inc. Cholesterol assays for quantifying extracellular vesicles
EP3858332A1 (en) 2020-01-31 2021-08-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bottom-up assembly of synthetic extracellular vesicles
EP4099984A4 (en) * 2020-02-05 2024-05-01 Diadem Biotherapeutics Inc. Artificial synapses
KR102688170B1 (en) * 2020-02-10 2024-07-24 주식회사 엑소스템텍 Exosome comprising photocleavable protein and Use thereof
WO2021231425A1 (en) * 2020-05-11 2021-11-18 Strm.Bio Incorporated Compositions and methods related to megakaryocyte-derived extracellular vesicles
KR102341138B1 (en) * 2020-05-31 2021-12-21 주식회사 엑소코바이오 Exosomes comprising exosomal membrane protein variant and manufacturing method thereof
US20230355803A1 (en) 2020-06-24 2023-11-09 Chameleon Biosciences, Inc. Extracellular vesicles with immune modulators
WO2022040223A1 (en) * 2020-08-17 2022-02-24 Codiak Biosciences, Inc. Methods of treating cancer
WO2022050725A1 (en) * 2020-09-04 2022-03-10 재단법인대구경북과학기술원 Method for screening immunogenic anticancer activity cytokine, and composition for preventing or treating cancer disease, comprising il-15 as active ingredient
EP4267970A1 (en) * 2020-12-22 2023-11-01 Verily Life Sciences LLC Methods for assaying target proteins on extracellular vesicles in plasma
CN112646781B (en) * 2020-12-25 2023-07-25 广东省人民医院 Exosome containing human ACE2 protein and application thereof
CN113040877B (en) * 2021-03-11 2022-07-22 上海市东方医院（同济大学附属东方医院） Infusion exosome system for treating abdominal diseases based on fascia clearance concept
CN113462645B (en) * 2021-03-26 2023-11-28 上海瑞开投资管理有限公司 Composition comprising NK cells and exosomes of plant origin, uses thereof and products comprising same
WO2022215078A1 (en) * 2021-04-07 2022-10-13 Ramot At Tel-Aviv University Ltd. Modified cannabinoids and uses thereof
WO2022250880A1 (en) * 2021-05-25 2022-12-01 Malcolm Thomas Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases
CA3226019A1 (en) 2021-07-20 2023-01-26 Ags Therapeutics Sas Extracellular vesicles from microalgae, their preparation, and uses
EP4388314A1 (en) * 2021-08-18 2024-06-26 Universität Duisburg-Essen A biomarker indicating the therapeutic efficacy of extracellular vesicle (ev)-preparations
CN113866413B (en) * 2021-09-29 2023-05-30 上海市同济医院 Colorectal cancer diagnosis marker and application thereof
WO2023144127A1 (en) 2022-01-31 2023-08-03 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
CN114561347A (en) * 2022-02-25 2022-05-31 和携科技有限公司 Culture medium and culture method of adipose-derived mesenchymal stem cells
WO2023195570A1 (en) * 2022-04-08 2023-10-12 이왕재바이오연구소 주식회사 Anticancer compositoin comprising superoxide dismutase
CN114807023B (en) * 2022-04-29 2024-03-15 中山大学·深圳 Cell membrane vesicle and preparation method and application thereof
CN114763533B (en) * 2022-05-17 2024-02-23 深圳市第二人民医院(深圳市转化医学研究院) Method for in-situ growth of nano-selenium on surface of exosome and obtained selenized exosome
WO2023229366A1 (en) * 2022-05-24 2023-11-30 Shiftbio Co., Ltd. Surface-engineered extracellular vesicles and therapeutic uses thereof
WO2023232976A1 (en) 2022-06-03 2023-12-07 Ags Therapeutics Sas Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
CN115047186B (en) * 2022-06-15 2023-02-14 暨南大学 Exosome detection method
EP4309660A1 (en) 2022-07-18 2024-01-24 Lietuvos Sveikatos Mokslu Universitetas Extracellular vesicles and particles from immune cells for providing anticancer activity
WO2024088808A1 (en) 2022-10-24 2024-05-02 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof
CN117603362A (en) * 2023-03-22 2024-02-27 北京恩康医药有限公司 Engineered extracellular vesicles
WO2024206778A1 (en) * 2023-03-30 2024-10-03 Exoone Bio. Co., Ltd. Radiolabeled exosome and method and kit for preparing same
CN117018217B (en) * 2023-10-10 2024-01-30 天津外泌体科技有限公司 Application of GNAI2 as extracellular vesicle scaffold protein, extracellular vesicle, preparation method and application thereof
CN117723758B (en) * 2023-12-14 2024-09-13 陕西脉元生物科技有限公司 Application of reagent for detecting anti-SLC 3A2 autoantibody in diagnosis of nervous system autoimmune disease
CN118340915A (en) * 2024-06-13 2024-07-16 北京恩泽康泰生物科技有限公司 Cytokine loading system, preparation method and application

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747660A (en) 1995-11-06 1998-05-05 The University Of Colorado Nucleic acid encoding prostaglandin F2α receptor regulatory protein
CA2411542A1 (en) 2000-06-09 2001-12-13 Teni Boulikas Encapsulation of polynucleotides and drugs into targeted liposomes
EP1417229B1 (en) * 2001-08-17 2011-06-15 Exothera L.L.C. Methods and compounds for the targeting of protein to exosomes
US20040049010A1 (en) 2001-10-26 2004-03-11 Warren Bridget A Transmembrane proteins
US7803906B2 (en) 2002-03-22 2010-09-28 Gene Signal International Sa Composition comprising an angiogenesis related protein
JP5129149B2 (en) 2005-10-31 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Compositions and methods for treating and diagnosing cancer
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
CN102497887A (en) * 2009-04-17 2012-06-13 Isis创新公司 Composition for delivery of genetic material
AU2011316477A1 (en) 2010-10-11 2013-05-02 Medsaic Pty Ltd Assay for disease detection
US20130071403A1 (en) 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
US9777042B2 (en) 2011-12-15 2017-10-03 Morehouse School Of Medicine Method of purifying HIV/SIV Nef from exosomal fusion proteins
EP2687219A1 (en) * 2012-07-18 2014-01-22 Universität Duisburg-Essen Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
EP2922861A4 (en) 2012-11-26 2016-09-14 Caris Life Sciences Switzerland Holdings Gmbh Biomarker compositions and methods
BR122021008308B1 (en) 2012-12-12 2022-12-27 The Broad Institute, Inc. CRISPR-CAS COMPONENT SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION
AU2014231770B2 (en) 2013-03-13 2020-01-30 The University Of Queensland A method of isolating cells for therapy and prophylaxis
SG11201601939VA (en) * 2013-09-16 2016-04-28 Agency Science Tech & Res Method
KR20150043937A (en) 2013-10-15 2015-04-23 삼성전자주식회사 A compositon for diagnosing a liver cancer in a subject, method for diagnosing a liver cancer in a subject and method for obtaining information for diagnosing a liver cancer in a subject
LT3076949T (en) * 2013-12-04 2019-12-10 Univ Texas Method for isolating cancer cell-derived exoxomes
US10772911B2 (en) * 2013-12-20 2020-09-15 Advanced ReGen Medical Technologies, LLC Cell free compositions for cellular restoration and methods of making and using same
CR20160307A (en) * 2013-12-20 2016-11-08 Advanced Regen Medical Tech Llc Compositions for cellular restoration and methods of making and using same
JP2017513818A (en) * 2014-03-15 2017-06-01 ノバルティス アーゲー Treatment of cancer using chimeric antigen receptors
AU2015330855A1 (en) 2014-10-09 2017-04-27 Celularity Inc. Placenta-derived adherent cell exosomes and uses thereof
EP3223856A4 (en) * 2014-10-27 2018-05-02 University of Central Florida Research Foundation, Inc. Methods and compositions for natural killer cells
WO2016077639A2 (en) 2014-11-12 2016-05-19 VL27, Inc. Nanovesicular therapies
CA3017571A1 (en) * 2015-03-16 2016-09-22 Duncan Ross Method of treatment comprising membrane-enclosed vesicle
WO2016168680A1 (en) 2015-04-17 2016-10-20 Exocyte Therapeutics Pte Ltd. Method for developing exosome-based vaccines
US10427129B2 (en) 2015-04-17 2019-10-01 LLT International (Ireland) Ltd. Systems and methods for facilitating reactions in gases using shockwaves produced in a supersonic gaseous vortex
WO2016187717A1 (en) * 2015-05-26 2016-12-01 Exerkine Corporation Exosomes useful for genome editing
KR102386735B1 (en) * 2015-11-06 2022-04-14 주식회사 제넥신 Formulation for modified interleukin-7 fusion protein
WO2017117585A1 (en) 2015-12-30 2017-07-06 The Regents Of The University Of California Methods for enhanced production and isolation of cell-derived vesicles
JP2019513019A (en) 2016-03-15 2019-05-23 コディアック バイオサイエンシズ インコーポレイテッド Therapeutic membrane vesicles
US20190125848A1 (en) * 2016-03-30 2019-05-02 Dana-Farber Cancer Institute, Inc. Dendritic cell-extracellular vesicle fusions and methods of using same
US20180128833A1 (en) * 2016-11-08 2018-05-10 Metaclipse Therapeutics Corporation Methods of treating with tumor membrane vesicle-based immunotherapy and predicting therapeutic response thereto
WO2018226758A2 (en) 2017-06-05 2018-12-13 The Regents Of The University Of California Methods for enhanced production and isolation of cell-derived vesicles and treatment of inflammation and neurological damage
EP3672573A4 (en) * 2017-08-25 2021-05-26 Codiak BioSciences, Inc. Preparation of therapeutic exosomes using membrane proteins
SG11202005049QA (en) 2017-12-28 2020-07-29 Codiak Biosciences Inc Exosomes for immuno-oncology and anti-inflammatory therapy

Also Published As

Publication number Publication date
US10723782B2 (en) 2020-07-28
KR20200108275A (en) 2020-09-17
US12030924B2 (en) 2024-07-09
JP2021508691A (en) 2021-03-11
EP3731849A4 (en) 2021-12-01
CO2020009091A2 (en) 2020-12-21
EP3731849A2 (en) 2020-11-04
US20240010705A1 (en) 2024-01-11
BR112020013131A2 (en) 2020-12-08
CL2020001691A1 (en) 2020-11-13
JP2023133470A (en) 2023-09-22
CA3085471A1 (en) 2019-07-04
US20190202892A1 (en) 2019-07-04
PH12020550805A1 (en) 2021-05-31
AU2018394238A1 (en) 2020-06-18
US20200407419A1 (en) 2020-12-31
JP7507090B2 (en) 2024-06-27
CN111655271A (en) 2020-09-11
EA202091134A1 (en) 2020-11-20
WO2019133934A3 (en) 2019-08-29
MX2020006672A (en) 2020-08-31
IL275600A (en) 2020-08-31
WO2019133934A2 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
IL275600A (en) Exosomes for immuno-oncology and anti-inflammatory therapy
GB201707153D0 (en) Therapy
GB201715194D0 (en) Compounds and their therapeutic use
IL270011B (en) Therapeutic compounds and methods
GB201719646D0 (en) Therapy
GB201708663D0 (en) Therapy
GB201617064D0 (en) Compounds and their therapeutic use
GB201519644D0 (en) Therapy and pharmaceutical composition
GB201715430D0 (en) Therapy
GB201713936D0 (en) Pharmaceutical combinations for the treatment of cancer
GB201707945D0 (en) Cnacer therapy
GB201707183D0 (en) Macrophage-based therapy
GB201703453D0 (en) Therapy
GB201706224D0 (en) Combination therapy
GB201706233D0 (en) Combination therapy
GB201706249D0 (en) Combination therapy
GB201706248D0 (en) Combination therapy
GB201706247D0 (en) Combination therapy
GB201706221D0 (en) Combination therapy
GB201706222D0 (en) Combination therapy
GB201706223D0 (en) Combination therapy
GB201706246D0 (en) Combination therapy
GB201706225D0 (en) Combination therapy
GB201706226D0 (en) Combination therapy
GB201706227D0 (en) Combination therapy